Notable Labs

Notable Labs Free Cash Flow

The Free Cash Flow (FCF) of Notable Labs (NTBLQ) as of Nov 8, 2026 is -13.78 M USD. In the previous year, Free Cash Flow (FCF) was -32.40 M USD — a change of -57.47% (higher).

Free Cash Flow

-13.78 MUSD

YoY

-57.47%

Last updated:

Free Cash Flow (FCF) of Notable Labs is 2023 -13.78 M USD. Free Cash Flow (FCF) of Notable Labs was 2022 -32.40 M USD. It decreases by -57.47% higher compared to the previous year.

The Notable Labs Free Cash Flow history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Free Cash Flow
Date
Free Cash Flow
Jan 1, 2016
-13.90 M USD
Jan 1, 2017
-10.30 M USD
Jan 1, 2018
-17.91 M USD
Jan 1, 2019
-13.16 M USD
Jan 1, 2020
-23.43 M USD
Jan 1, 2021
-26.45 M USD
Jan 1, 2022
-32.40 M USD
Jan 1, 2023
-13.78 M USD
The Notable Labs Free Cash Flow history
YEARFree Cash FlowYoY
-13.78 MUSD-57.47%
-32.40 MUSD+22.50%
-26.45 MUSD+12.89%
-23.43 MUSD+78.04%
-13.16 MUSD-26.52%
-17.91 MUSD+73.88%
-10.30 MUSD-25.90%
-13.90 MUSD+4.59%
-13.29 MUSD-3.42%
-13.76 MUSD—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Notable Labs Stock analysis

What does Notable Labs do? Notable Labs Ltd, formerly Vascular Biogenics Ltd, is an Israel-based clinical-stage biopharmaceutical company developing targeted medicines for cancer and immune-inflammatory diseases. The company leverages two platform technologies: Vascular Targeting System (VTS), a gene-based approach targeting newly formed blood vessels, and Monocyte Targeting Technology (MTT), an antibody-based method inhibiting monocyte migration. Its product candidates aim to improve patient outcomes by overcoming limitations of current treatments. The firm's pipeline focuses on difficult-to-treat conditions, with VTS and MTT serving as the core technologies for developing therapeutics. VTS targets cancer by focusing on blood vessel formation, while MTT addresses immune-inflammatory diseases through monocyte migration control. These technologies enable the creation of next-generation medicines that address unmet medical needs. Notable Labs Ltd sells its product candidates to pharmaceutical companies and healthcare providers for further development and clinical trials. The primary buyers are biopharmaceutical firms seeking innovative therapies, particularly those targeting cancer and immune-inflammatory conditions. The company's revenue model relies on licensing agreements and partnerships with these industry players to advance its pipeline. Notable Labs is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Notable Labs stock

Free Cash Flow (FCF) of Notable Labs is -13.78 M USD in 2023.

Free Cash Flow (FCF) of Notable Labs changed from -32.40 M USD to -13.78 M USD, representing a -57.47% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Free Cash Flow (FCF) Notable Labs since 2006 – with annual values, charts, and detailed analysis.

Free Cash Flow is the cash available after capital expenditures. It represents the cash a company can use for dividends, debt reduction, or reinvestment.

FCF = Operating Cash Flow - Capital Expenditures

Free Cash Flow (FCF)'s USD is a key factor for investors. Changes in this metric can signal improving or deteriorating fundamentals, directly impacting the stock price. On Eulerpool, you can track Free Cash Flow (FCF)'s Notable Labs historically and in real time.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Cash Flow — Notable Labs

All Key Metrics — Notable Labs